FDA Clears Monte Rosa’s MRT-8102 IND for Inflammatory Diseases
Monte Rosa Therapeutics has received FDA approval to begin clinical trials for MRT-8102, a novel molecular glue degrader (MGD)...
MP0533 Shows Promise in AML Trial
Molecular Partners released positive Phase 1/2a trial data for MP0533, a tetraspecific T-cell engager targeting relapsed/refractory acute myeloid leukemia...
Polypid’s SHIELD II Trial Delivers Transformative Results
PolyPid Ltd. announced positive topline results from its Phase 3 SHIELD II trial of D-PLEX100, demonstrating a statistically significant...
Polypid Shield’s Phase 3 Results: Paradigm Shift in Surgical Infection Prevention
PolyPid Ltd. announced positive topline results from its Phase 3 SHIELD II trial, showing D-PLEX100 significantly reduced surgical site...
Unprecedented 76-Week Barzolvolimab Results in Chronic Urticaria
Celldex released 76-week data from a Phase 2 trial of barzolvolimab for chronic spontaneous urticaria (CSU). Seven months after...
Revumenib Data from BEAT AML Trial Published in JCO & Presented at EHA 2025
Syndax Pharmaceuticals announced positive results from the BEAT AML trial of revumenib combined with venetoclax and azacitidine (ven/aza) in...
Apex Labs Expands Macrodose Psilocybin PTSD Trial
Apex Labs Ltd. received approval from Israel’s Ministry of Health to expand its phase 2b clinical trial, SUMMIT-90, for...
Neurostimulation Trial for Opioid Disorder Shows Promising Results
Spark Biomedical concluded enrollment for its pivotal clinical trial using transcutaneous auricular neurostimulation (tAN) to improve treatment retention for...
Atai & Beckley Psychedelic Merger Creates Global Mental Health Leader
Atai Life Sciences and Beckley Psytech are merging in an all-stock transaction, creating atai Beckley, a leading mental health...
Promising Data: Alrizomadlin in Solid Tumors
Ascentage Pharma released Phase II clinical trial data for its MDM2-p53 inhibitor, alrizomadlin (APG-115), at the 2025 ASCO Annual...